Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
Salud Publica Mex
; 54(1): 47-59, 2012.
Article
in En
| MEDLINE
| ID: mdl-22286828
ABSTRACT
OBJECTIVE:
The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. MATERIAL ANDMETHODS:
A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009.RESULTS:
ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760.CONCLUSIONS:
Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.
Full text:
1
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Respiratory Syncytial Virus Infections
/
Antibodies, Monoclonal, Humanized
/
Infant, Premature, Diseases
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Humans
/
Newborn
Country/Region as subject:
Mexico
Language:
En
Journal:
Salud Publica Mex
Year:
2012
Type:
Article